NCT07674862已完成1 期
A Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Phase I Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetics of ETD-001 Gel in Healthy Chinese Subjects
Etern Therapeutics Wuxi Limited1 个研究点 分布在 1 个国家目标入组 56 人开始时间: 2026年3月16日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 56
- 试验地点
- 1
- 主要终点
- To evaluate the safety and tolerability of ETD-001 in healthy Chinese subjects.
研究概览
简要总结
This is a single-center, randomized, double-blind, placebo-controlled Phase I clinical study, which comprises two parts: Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) in healthy subjects.Three dose groups are pre-scheduled for the SAD part. After the safety and tolerability of subjects in the second SAD dose group are confirmed, the MAD part will be initiated upon evaluation by the Safety Review Committee (SRC). Four dose groups are tentatively planned for the MAD part.Each dose group will enroll 8 subjects, who will be randomized at a 6:2 ratio to receive either ETD-001 gel or placebo.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Sequential
- 主要目的
- Other
- 盲法
- Triple (Participant, Care Provider, Investigator)
入排标准
- 年龄范围
- 16 Years 至 60 Years（Child, Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Subjects meeting any of the following
排除标准
- •will be excluded from this trial:
- •Fully understand the purpose, nature and methodology of the trial, as well as potential adverse reactions, and voluntarily sign the informed consent form.
- •Healthy male or female Chinese subjects aged between 18 and 60 years inclusive (age determined on the date of signing the informed consent form).
- •Body Mass Index (BMI) ranging from 19 to 26 kg/m² inclusive; male subjects shall weigh no less than 50 kg, and female subjects no less than 45 kg.
- •No skin rupture, lesions (including skin lesions caused by dermatoses), redness, rash, pigmentation, tattoos, excessive hair or abnormal warmth at the intended application site.
- •Subjects are deemed to be in good general health by the investigator based on medical history, physical examination, vital signs, 12-lead electrocardiogram, laboratory tests (blood routine, urine routine, blood biochemistry) and viral serology results (all findings are normal or abnormalities are clinically insignificant).
- •Female subjects must be non-pregnant and non-lactating. All subjects, regardless of gender, must agree to use medically approved effective contraception from the screening period until 6 months after the last dose. They shall not donate sperm or ova during the study period and within 6 months after the last dose.
- •Exclusion Criteria:
- •Subjects who are allergic to the investigational drug or any of its excipients; those with allergic diathesis (e.g., allergy to two or more types of drugs, foods or pollen); or those with severe systemic allergic diseases (e.g., severe asthma, allergic rhinitis, etc.).
- •Subjects with clinically significant abnormal medical conditions or factors, including but not limited to metabolic, hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, urological, endocrine, neurological and psychiatric diseases, or other conditions deemed inappropriate for participation in this study by the investigator.
- •Subjects who have taken or are expected to take any prescription drugs, over-the-counter medications, vitamin products, health supplements or traditional 4.Chinese medicinal preparations within 14 days prior to the first dose, or within 5 half-lives of the study drug (whichever is longer); or those who have consumed foods or beverages that may induce or inhibit hepatic metabolic enzymes (e.g., grapefruit) within 7 days before dosing.
- •Subjects with abnormal liver or renal function:
- •Total Bilirubin (TBIL) > 1.5 × ULN;
- •AST or ALT ≥ 1.5 × ULN;
- •Blood Urea Nitrogen (BUN) and Creatinine (CRE) > 1.5 × ULN. 5.Subjects with confirmed positive test results for hepatitis B, hepatitis C, Human Immunodeficiency Virus (HIV) or syphilis at screening.
- •6.Subjects with a history of drug abuse within the past five years, those who have used illicit drugs within 3 months prior to screening, or those with a positive drug abuse screening result at baseline.
- •7.Subjects consuming more than 14 units of alcohol per week within 3 months prior to screening (1 alcohol unit = 360 mL beer, or 45 mL spirits with 40% alcohol content, or 150 mL wine); those who have consumed alcoholic products within 48 hours before receiving the investigational drug; or those with a positive breath alcohol test at baseline.
- •8.Subjects smoking more than 5 cigarettes per day or habitually using nicotine-containing products within 3 months prior to screening.
- •9.Subjects who have ingested any foods or beverages containing caffeine or xanthine or their metabolites (e.g., coffee, tea, chocolate) within 48 hours prior to the first dose.
- •10.Subjects who have received blood or blood products, or donated/lost more than 400 mL of blood within 3 months prior to the first dose; or those who plan to donate blood during the trial and within 3 months after trial completion.
- •11.Subjects who have participated in another clinical trial and taken other investigational products within 30 days prior to the first dose, or within 5 half-lives of the study drug (whichever is longer).
- •12.Subjects who have suffered from clinically significant severe illnesses or undergone major surgery within 28 days prior to the first dose, or who are expected to receive major surgery during the trial.
- •13.Subjects with difficult venous access or a history of needle phobia or hemophobia.
- •14.Female subjects with a positive pregnancy test at screening or baseline, who are breastfeeding or planning to become pregnant.
- •15.Subjects with a history of chronic skin diseases (e.g., eczema, psoriasis, etc.).
- •16.Any other conditions that, in the investigator's judgment, may prevent the subject from giving informed consent or complying with the trial protocol, or may compromise trial results or the subject's personal safety if the subject participates in the trial.
研究组 & 干预措施
ETD-001 gel
Experimental
QD，topical administration
干预措施: Dose 1 (Drug)
ETD-001 gel
Experimental
QD，topical administration
干预措施: dose 2 (Drug)
PLACEBO
Placebo Comparator
QD，topical administration
干预措施: Dose 1 (Drug)
PLACEBO
Placebo Comparator
QD，topical administration
干预措施: dose 2 (Drug)
ETD-001 gel
Experimental
QD，topical administration
干预措施: dose 3 (Drug)
PLACEBO
Placebo Comparator
QD，topical administration
干预措施: dose 3 (Drug)
结局指标
主要结局
To evaluate the safety and tolerability of ETD-001 in healthy Chinese subjects.
时间窗: Up to Day 21
Number of participants with treatment-related adverse events as assessed by CTCAE v6.0
次要结局
- To evaluate the pharmacokinetic characteristics of ETD-001 gel in healthy Chinese subjects.(Up to Day 21)
研究者
研究点 (1)
Loading locations...
相似试验
尚未招募
1 期
A Study of SSS68 Following a Single Subcutaneous Administration in Healthy Adult ParticipantsNCT07606976Shenyang Sunshine Pharmaceutical Co., LTD.50
尚未招募
1 期
Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of SSS67 in Healthy Adult Participants Via Single Intravenous InfusionNCT07487545Shenyang Sunshine Pharmaceutical Co., LTD.52
招募中
1 期
A Clinical Trial Evaluating the Monkeypox Recombinant Protein VaccineHealth VolunteerNCT07495202Shanghai JunTop Biosciences Co., LTD180
已完成
不适用
A Study in Healthy Subjects to Assess the Safety and Tolerability of a 120-hour Continuous Infusion of M6229NCT07285603Matisse Pharmaceuticals15
尚未招募
1 期
A Study of HS-20136-2 in Healthy ParticipantsNCT07483437Jiangsu Hansoh Pharmaceutical Co., Ltd.38